BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34982354)

  • 1. Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial.
    Kawahara T; Taira N; Shiroiwa T; Hagiwara Y; Fukuda T; Uemura Y; Mukai H
    Qual Life Res; 2022 Jun; 31(6):1829-1836. PubMed ID: 34982354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
    Musoro JZ; Coens C; Greimel E; King MT; Sprangers MAG; Nordin A; van Dorst EBL; Groenvold M; Cocks K; Velikova G; Flechtner HH; Bottomley A;
    Gynecol Oncol; 2020 Nov; 159(2):515-521. PubMed ID: 32972782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy.
    Musoro JZ; Sodergren SC; Coens C; Pochesci A; Terada M; King MT; Sprangers MAG; Groenvold M; Cocks K; Velikova G; Flechtner HH; Bottomley A;
    Colorectal Dis; 2020 Dec; 22(12):2278-2287. PubMed ID: 32767619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients.
    Dirven L; Musoro JZ; Coens C; Reijneveld JC; Taphoorn MJB; Boele FW; Groenvold M; van den Bent MJ; Stupp R; Velikova G; Cocks K; Sprangers MAG; King MT; Flechtner HH; Bottomley A
    Neuro Oncol; 2021 Aug; 23(8):1327-1336. PubMed ID: 33598685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimally Important Differences for Interpreting EORTC QLQ-C30 Scores in Patients With Advanced Breast Cancer.
    Musoro JZ; Coens C; Fiteni F; Katarzyna P; Cardoso F; Russell NS; King MT; Cocks K; Sprangers MA; Groenvold M; Velikova G; Flechtner HH; Bottomley A;
    JNCI Cancer Spectr; 2019 Sep; 3(3):pkz037. PubMed ID: 32328553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types.
    Musoro JZ; Coens C; Sprangers MAG; Brandberg Y; Groenvold M; Flechtner HH; Cocks K; Velikova G; Dirven L; Greimel E; Singer S; Pogoda K; Gamper EM; Sodergren SC; Eggermont A; Koller M; Reijneveld JC; Taphoorn MJB; King MT; Bottomley A;
    Eur J Cancer; 2023 Jul; 188():171-182. PubMed ID: 37257278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma.
    Musoro JZ; Bottomley A; Coens C; Eggermont AM; King MT; Cocks K; Sprangers MA; Groenvold M; Velikova G; Flechtner HH; Brandberg Y;
    Eur J Cancer; 2018 Nov; 104():169-181. PubMed ID: 30359910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma - Interpretation guidance derived from two randomized EORTC trials.
    Koller M; Musoro JZ; Tomaszewski K; Coens C; King MT; Sprangers MAG; Groenvold M; Cocks K; Velikova G; Flechtner HH; Bottomley A
    Lung Cancer; 2022 May; 167():65-72. PubMed ID: 35413526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 scores in patients with head and neck cancer.
    Musoro JZ; Coens C; Singer S; Tribius S; Oosting SF; Groenvold M; Simon C; Machiels JP; Grégoire V; Velikova G; Cocks K; Sprangers MAG; King MT; Bottomley A;
    Head Neck; 2020 Nov; 42(11):3141-3152. PubMed ID: 32627261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials.
    Gamper EM; Musoro JZ; Coens C; Stelmes JJ; Falato C; Groenvold M; Velikova G; Cocks K; Flechtner HH; King MT; Bottomley A;
    BMC Cancer; 2021 Oct; 21(1):1083. PubMed ID: 34620124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishing anchor-based minimally important differences (MID) with the EORTC quality-of-life measures: a meta-analysis protocol.
    Musoro ZJ; Hamel JF; Ediebah DE; Cocks K; King MT; Groenvold M; Sprangers MAG; Brandberg Y; Velikova G; Maringwa J; Flechtner HH; Bottomley A; Coens C;
    BMJ Open; 2018 Jan; 8(1):e019117. PubMed ID: 29326191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma.
    Reni M; Braverman J; Hendifar A; Li CP; Macarulla T; Oh DY; Riess H; Tempero M; Lu B; Marcus J; Joshi N; Botteman M; Dueck AC
    Ann Surg Oncol; 2021 Nov; 28(12):7545-7554. PubMed ID: 33813673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases.
    Raman S; Ding K; Chow E; Meyer RM; van der Linden YM; Roos D; Hartsell WF; Hoskin P; Wu JSY; Nabid A; Haas R; Wiggenraad R; Babington S; Demas WF; Wilson CF; Wong RKS; Zhu L; Brundage M
    Qual Life Res; 2018 Apr; 27(4):1089-1098. PubMed ID: 29188483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials.
    Maringwa JT; Quinten C; King M; Ringash J; Osoba D; Coens C; Martinelli F; Vercauteren J; Cleeland CS; Flechtner H; Gotay C; Greimel E; Taphoorn MJ; Reeve BB; Koch JS; Weis J; Smit EF; van Meerbeeck JP; Bottomley A;
    Support Care Cancer; 2011 Nov; 19(11):1753-60. PubMed ID: 20886240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishing Meaningful Change Thresholds in Patient-Reported Outcomes Among Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in ALTA-1L Trial.
    Beaumont JL; Lin HM; Goodman E; Yu H; Geiger A; Hudgens S
    Value Health; 2024 Feb; 27(2):182-189. PubMed ID: 37951539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial.
    Wallwiener M; Matthies L; Simoes E; Keilmann L; Hartkopf AD; Sokolov AN; Walter CB; Sickenberger N; Wallwiener S; Feisst M; Gass P; Fasching PA; Lux MP; Wallwiener D; Taran FA; Rom J; Schneeweiss A; Graf J; Brucker SY
    J Med Internet Res; 2017 Sep; 19(9):e322. PubMed ID: 28912116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal important differences in the EORTC QLQ-C30 in patients with advanced cancer.
    Bedard G; Zeng L; Zhang L; Lauzon N; Holden L; Tsao M; Danjoux C; Barnes E; Sahgal A; Poon M; Chow E
    Asia Pac J Clin Oncol; 2014 Jun; 10(2):109-17. PubMed ID: 23551530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methodological approach for determining the Minimal Important Difference and Minimal Important Change scores for the European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module (EORTC QLQ-HN43) exemplified by the Swallowing scale.
    Singer S; Hammerlid E; Tomaszewska IM; Amdal CD; Bjordal K; Herlofson BB; Santos M; Silva JC; Mehanna H; Fullerton A; Brannan C; Gonzalez LF; Inhestern J; Pinto M; Arraras JI; Yarom N; Bonomo P; Baumann I; Galalae R; Nicolatou-Galitis O; Kiyota N; Raber-Durlacher J; Salem D; Fabian A; Boehm A; Krejovic-Trivic S; Chie WC; Taylor K; Simon C; Licitra L; Sherman AC;
    Qual Life Res; 2022 Mar; 31(3):841-853. PubMed ID: 34272632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An international prospective study establishing minimal clinically important differences in the EORTC QLQ-BM22 and QLQ-C30 in cancer patients with bone metastases.
    Zeng L; Chow E; Zhang L; Tseng LM; Hou MF; Fairchild A; Vassiliou V; Jesus-Garcia R; Alm El-Din MA; Kumar A; Forges F; Chie WC; Bedard G; Bottomley A
    Support Care Cancer; 2012 Dec; 20(12):3307-13. PubMed ID: 22562607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying changes in scores on the EORTC-QLQ-C30 representing a change in patients' supportive care needs.
    Snyder CF; Blackford AL; Sussman J; Bainbridge D; Howell D; Seow HY; Carducci MA; Wu AW
    Qual Life Res; 2015 May; 24(5):1207-16. PubMed ID: 25398495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.